Patient characteristics
| . | LAC positive due to anti–β2 GPI antibodies, n = 10* . | LAC positive not due to anti-β2 antibodies, n = 10 . | LAC-negative SLE patients, n = 10 . |
|---|---|---|---|
| SLE | 5 | 10 | 10 |
| LLD | 3 | 0 | 0 |
| PAPS | 2 | 0 | 0 |
| ACL IgG | 9 | 7 | 3 |
| ACL IgM | 4 | 3 | 2 |
| Anti–β2GPI IgG | 10 | 0 | 0 |
| Anti–β2GPI IgM | 3 | 1 | 0 |
| Antiprothrombin IgG | 8 | 5 | 4 |
| Antiprothrombin IgM | 5 | 4 | 0 |
| Thrombosis | 10 | 1 | 3 |
| . | LAC positive due to anti–β2 GPI antibodies, n = 10* . | LAC positive not due to anti-β2 antibodies, n = 10 . | LAC-negative SLE patients, n = 10 . |
|---|---|---|---|
| SLE | 5 | 10 | 10 |
| LLD | 3 | 0 | 0 |
| PAPS | 2 | 0 | 0 |
| ACL IgG | 9 | 7 | 3 |
| ACL IgM | 4 | 3 | 2 |
| Anti–β2GPI IgG | 10 | 0 | 0 |
| Anti–β2GPI IgM | 3 | 1 | 0 |
| Antiprothrombin IgG | 8 | 5 | 4 |
| Antiprothrombin IgM | 5 | 4 | 0 |
| Thrombosis | 10 | 1 | 3 |
ACL indicates anticardiolipin antibodies.
Determined as described in Galli et al.4